PDB24 A COST-EFFECTIVENESS ANALYSIS OF IRBESARTAN IN THE TREATMENT OF HYPERTENSIVE PATIENTS WITH DIABETIC RENAL DISEASE  by Lee, TJ et al.
CONCLUSIONS: Based on a willingness to pay threshold of
500,000 SEK per QALY, somatropin (Norditropin®) is a cost-
effective treatment for GHD children.
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OBJECTIVES: To project the cumulative incidence of end-stage
renal disease (ESRD), life expectancy (LE) and costs of treating
hypertensive patients suffering from diabetic renal disease with
either irbesartan treatment or standard hypertension treatment in
South Korea. METHODS: A Markov model that simulated pro-
gression from microalbuminuria to nephropathy, doubling of
serum creatinine, ESRD and all-cause mortality in hypertensive
patients with diabetic renal diseases was adapted to South Korea.
Three strategies were compared: 1) early use of irbesartan (ie,
start treatment in subjects with microalbuminuria); versus 2) late
use of irbesartan (ie, as from overt nephropathy); or 3) standard
hypertension care (with comparable blood pressure control).
Cumulative incidence of ESRD, LE and costs were projected for
a hypothetical cohort of 1000 subjects. Treatment-speciﬁc pro-
gression and mortality probabilities were derived from published
trials: IRMA-2 (in microalbuminuria) and IDNT (in overt neph-
ropathy). Medical management and cost data per state as well as
ESRD outcomes data were obtained from local sources. A ﬂex-
ible time horizon up to 25 years and third party payer perspective
were used. Future LE and costs were discounted at 5% yearly.
RESULTS: When compared to standard blood pressure control,
early use of irbesartan was projected to reduce the cumulative
incidence of ESRD from 23.9% to 5.5%, save KW 9,383,748
(US$8,988), and add 0.39 life years per treated patient. Late use
of irbesartan produced higher net monetary beneﬁt than control
but was dominated by early use. The superiority of early use of
irbesartan over standard care was robust for most variables,
except for the time horizon. Break-even occurred after 12 years.
CONCLUSIONS: Early use of irbesartan in hypertensive
patients with diabetic renal diseases was projected to reduce the
incidence of ESRD, extend life and reduce costs; treating patients
with irbesartan at a later stage is still beneﬁcial, but to a lesser
extent.
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OBJECTIVES: The aim of this analysis was to evaluate the
long-term clinical and economic outcomes associated with
insulin detemir and Neutral Protamine Hagedorn (NPH) insulin
in combination with mealtime insulin aspart in patients with type
1 diabetes in Sweden, based on data from a recently published
2-year, multi-national, open-label, randomized, controlled trial
(RCT). METHODS: Long-term projections of the trial results
were based on a published and validated computer model
(CORE Diabetes Model). In the trial, insulin detemir was asso-
ciated with signiﬁcant improvements in glycemic control after 24
months (HbA1c 7.36% versus 7.58%, mean difference -0.22%,
P = 0.022) and major hypoglycemic events (69% risk reduction,
P = 0.001) versus NPH. Patients treated with detemir gained less
weight (1.7 versus 2.7 kg, P = 0.024). Based on these ﬁndings,
the model was used to estimate life-expectancy, quality-adjusted
life expectancy and both direct medical costs and indirect costs
(human capital approach). Future costs and clinical beneﬁts were
discounted at 3% per annum. RESULTS: Basal-bolus therapy
with insulin detemir was projected to improve life expectancy by
approximately 0.14 years (15.02  0.19 versus 14.88  0.18
years) and quality-adjusted life expectancy by 0.53 QALYs
versus NPH (8.35  0.11 versus 7.82  0.10 QALYs). Improve-
ments in QALYs were driven by avoided or delayed diabetes-
related complications and fewer insulin side effects. Direct
medical costs over patient lifetimes were approximately SEK
26,144 higher in the insulin detemir arm (SEK 995,025 
19,580 versus 968,881  19,769), leading to an incremental
cost-effectiveness ratio of SEK 49,757 per QALY gained. Cap-
turing indirect costs associated with lost productivity led to
insulin detemir being cost saving, by approximately SEK
106,257, compared to NPH (SEK 1,964,884  45,147 versus
2,071,142  42,548). CONCLUSIONS: The ﬁndings of this
analysis suggest that, compared to NPH, insulin detemir is likely
to be highly cost-effective from a healthcare payer perspective
and dominant from a societal perspective in patients with type 1
diabetes in Sweden.
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OBJECTIVES: The aim of the analysis was to estimate the cost-
effectiveness of human insulin treatment (current standard care)
in patients with type 2 diabetes compared with biphasic insulin
aspart (BIAsp) in those treated with insulin +/- OADs, from the
perspective of third party payers in the South African private
health care sector. METHODS: Clinical outcomes and baseline
characteristics were taken from an observational study of 208
patients. A baseline mean HbA1c of 10.1% was recorded in
patient whose average age was 52.8 years. The cost-effectiveness
ratio was estimated as the incremental cost per life-year and
quality-adjusted life-year gained of BIAsp treatment. Research
was conducted to collect cost data in type 2 diabetics: resource
utilisation, treatment costs, complication costs at year 1 and
subsequent years were investigated using insurance data. Life-
years gained were based on a 30-year follow-up using a pub-
lished and validated Markov diabetes outcomes model, adjusted
for South African risks and non-speciﬁc mortality. RESULTS: In
the base-case analysis the BIAsp group had better clinical out-
comes and lower lifetime costs. The estimated discounted gain in
life-years of biphasic insulin aspart was 0.25 years, and 0.39
years with utility adjustment. The incremental cost per life-year
gained and cost per-QALY were dominant. Total costs were 7%
lower in the BIAsp group; treatment cost associated with BIAsp
was 39% higher; cost savings were greatest in patients experi-
encing cardiovascular, renal or major hypoglycaemic complica-
tions. The acceptability curve showed a 99.8% probability that
of biphasic insulin aspart is cost effective in the base case scenario
at the WHO’s suggested threshold of three times GDP per capita.
HbA1c effects were the most sensitive variable to ﬁnal outcomes.
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